三 DNA 甲基化特征作为结直肠癌患者新型预后生物标志物的发展。
The Development of Three-DNA Methylation Signature as a Novel Prognostic Biomarker in Patients with Colorectal Cancer.
机构信息
Department of Biological Sciences, Life Sciences College, Zhaoqing University, Zhaoqing 526061, China.
Chengdu 23 Mofang Biotechnology Co., Ltd., Chengdu 610000, China.
出版信息
Biomed Res Int. 2020 Nov 25;2020:3497810. doi: 10.1155/2020/3497810. eCollection 2020.
AIMS
The prognosis of colorectal cancer (CRC) remains poor. This study aimed to develop and validate DNA methylation-based signature model to predict overall survival of CRC patients.
METHODS
The methylation array data of CRC patients were retrieved from The Cancer Genome Atlas (TCGA) database. These patients were divided into training and validation datasets. A risk score model was established based on Kaplan-Meier and multivariate Cox regression analysis of training cohort and tested in validation cohort.
RESULTS
Among total 14,626 DNA methylation candidate markers, we found that a three-DNA methylation signature (NR1H2, SCRIB, and UACA) was significantly associated with overall survival of CRC patients. Subgroup analysis indicated that this signature could predict overall survival of CRC patients regardless of age and gender.
CONCLUSIONS
We established a prognostic model consisted of 3-DNA methylation sites, which could be used as potential biomarker to evaluate the prognosis of CRC patients.
目的
结直肠癌（CRC）的预后仍然较差。本研究旨在建立和验证基于 DNA 甲基化的签名模型，以预测 CRC 患者的总生存率。
方法
从癌症基因组图谱（TCGA）数据库中检索 CRC 患者的甲基化阵列数据。这些患者被分为训练集和验证集。基于训练队列的 Kaplan-Meier 和多变量 Cox 回归分析建立风险评分模型，并在验证队列中进行测试。
结果
在总共 14626 个 DNA 甲基化候选标记中，我们发现三个 DNA 甲基化标记（NR1H2、SCRIB 和 UACA）与 CRC 患者的总生存率显著相关。亚组分析表明，该标志物可预测 CRC 患者的总生存率，无论其年龄和性别如何。
结论
我们建立了一个由 3 个 DNA 甲基化位点组成的预后模型，可作为评估 CRC 患者预后的潜在生物标志物。
Zotero 插件